| |
DVD(-)
|
DVT(+)
| |
|---|
|
Characteristics
|
n = 318
|
n = 56
|
p
|
|---|
|
Age
|
68.2 ± 11.6
|
( 25-90 )
|
74.5 ± 7.8
|
(45-86)
|
<0.00001
|
| Age≧75 yr |
106
| |
32
| |
0.001
|
|
Age < 75 yr
|
212
| |
24
| | |
|
Gender(male/female)
|
60/258
| |
5/51
| |
0.070
|
|
BMI(Kg/m2)
|
24.7 ± 4.2
|
(13.7-41.4)
|
25.8 ± 3.8
|
(20.1-35.1)
|
0.088
|
| BMI≧30 |
37
| |
10
| |
0.195
|
|
BMI < 30
|
281
| |
46
| | |
|
Risk factors
|
176(55.3%)
| |
38(67.9%)
| |
0.081
|
|
TKA/THA
|
125/193
| |
35/21
| |
0.001
|
|
OA/RA
|
273/46
| |
48/7
| |
0.697
|
|
Seroconvertion of IgG-class Anti-PF4/heparin Ab
|
54(17.0%)
| |
20(35.7%)
| |
0.001
|
|
Treatment
| | | | | |
|
UFH
|
89
|
(27.7%)
|
16
|
(28.6%)
|
0.890
|
|
LMWH
|
81
|
(25.5%)
|
14
|
(25.0%)
|
0.940
|
|
Fondaparinux
|
73
|
(23.0%)
|
8
|
(14.3%)
|
0.146
|
|
Others
|
37
|
(11.6%)
|
13
|
(23.2%)
| |
|
Aspirin
|
31
|
(9.7%)
|
12
|
(21.4%)
| |
|
Warfarin
|
5
|
(1.6%)
|
0
| | |
|
Cilostazol
|
26
|
(8.2%)
|
11
|
(19.6%)
| |
|
No medication
|
39
|
(12.3%)
|
5
|
(8.9%)
|
0.475
|
- Abbreviations: DVT; deep vein thrombosis; BMI; body mass index, TKA; total knee arthroplasty, THA; total hip arthroplasty, OA; osteoarthritis, RA; rheumatoid arthritis, UFH; unfractionated heparin, LMWH; low-molecular weight heparin
